SEL-212
Selecta Biosciences
[]
selecta biosciences announces presentation of data from phase 3 dissolve program of sel-212 in chronic refractory gout during late-breaking session at the eular 2023 european congress of rheumatology - globenewswire $selb 
EDIT,CRSP,CRBU,DTIL, PACB,CLLS,NTLA,BEAM,SGMO, BLUE,VERV,GRPH,PRME